Combined treatment with selective cyclooxygenase-2 inhibitor and fluorinated pyrimidines for liver metastasis of colon cancer

Oncology Reports

Volumn 11, Issue 1, 2004, Pages 167-171

  Matsunaga, Nobuo ^a   Yamada, Nobuya ^a   Ohira, Masaichi ^a   Tachimori, Akiko ^a   Nishiguchi, Yukio ^a   Nishino, Hiroji ^a   Seki, Syuichi ^a   Hirakawa, Kosei ^a  

^a OSAKA CITY UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

5 FU; Colon cancer; Combined therapy; COX 2 inhibitor; Liver metastasis

Indexed keywords

ANTINEOPLASTIC AGENT; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITOR; ETODOLAC; FLUOROURACIL; ISOENZYME; MEMBRANE PROTEIN; PROSTAGLANDIN SYNTHASE; PROSTAGLANDIN SYNTHASE INHIBITOR; PTGS2 PROTEIN, HUMAN;

ANIMAL; ARTICLE; BAGG ALBINO MOUSE; CANCER INVASION; CELL DIVISION; CELL MOTION; COLON TUMOR; COMPARATIVE STUDY; DOSE RESPONSE; DRUG ANTAGONISM; DRUG EFFECT; DRUG SCREENING; FEMALE; HUMAN; LIVER TUMOR; METASTASIS; METHODOLOGY; MOUSE; PATHOLOGY; TUMOR CELL LINE;

ANIMALS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CELL DIVISION; CELL LINE, TUMOR; CELL MOVEMENT; COLONIC NEOPLASMS; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITORS; CYCLOOXYGENASE INHIBITORS; DOSE-RESPONSE RELATIONSHIP, DRUG; ETODOLAC; FEMALE; FLUOROURACIL; HUMANS; ISOENZYMES; LIVER NEOPLASMS; MEMBRANE PROTEINS; MICE; MICE, INBRED BALB C; NEOPLASM INVASIVENESS; PROSTAGLANDIN-ENDOPEROXIDE SYNTHASES; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 3543143150     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or.11.1.167     Document Type: Article

References (41)

1. Cancer Statistics in Japan 2001. The Editorial Board of the Cancer Statistics in Japan.
2. Kune GA, Kune S and Watson LF: Colorectal cancer risk, chronic illnesses, operations and medications: case control results from the Melbourne Colorectal Cancer Study. Cancer Res 48: 4399-4404, 1988.
3. Thun MJ, Namboodiri MM and Heath Jr CW: Aspirin use and reduced risk of fatal colon cancer. N Engl J Med 325: 1593-1596, 1991.
4. Giovannucci E, Egan KM, Hunter DJ, Stampfer MJ, Colditz GA, Willet WC and Speizer FE: Aspirin and the risk of colorectal cancer in woman. N Engl J Med 333: 609-614, 1995.
5. Suh O, Mettlin C and Petrelli NJ: Aspirin use, cancer, and polyps of the large bowel. Cancer 72: 1171-1177, 1993. (Pubitemid 23224982)
6. Peleg II, Maibach HT, Brown SH and Wilcox CM: Aspirin and nonsteroidal anti-inflammatory drugs use and the risk of subsequent colorectal cancer. Arch Intern Med 154: 394-399, 1994. (Pubitemid 24072212)
7. Waddell WR and Loughry RW: Sulindac for polyposis of the colon. J Surg Oncol 24: 83-87, 1983. (Pubitemid 13004158)
8. Giardiello FM, Hamilton SR, Krush AJ, et al: Treatment of colonic and rectal adenomas with sulindac in familial adenomatous polyposis. N Engl J Med 328: 1313-1316, 1993. (Pubitemid 23131373)
9. Steinbach G, Lynch PM, Phillips RK, Hawk E, Gordon GB, Wakabayashi N and Saunders B: The effect of celecoxib, a cyclooxygenase-2 inhibitor, in familial adenomatous polyposis. N Engl J Med 342: 1946-1952, 2000. (Pubitemid 30419089)
10. Smith WL, DeWitt DL and Garavito RM: Cyclooxygenases: structural, cellular, and molecular biology. Annu Rev Biochem 69: 145-182, 2000.
11. Williams CS, Mann M and DuBois RN: The role of cyclooxygenases in inflammation, cancer, and development. Oncogene 18: 7908-7916, 1999. (Pubitemid 30066236)
12. Eberhart CE, Coffy RJ, Radhika A, Giardiello FM, Ferrenbach S, and Dubois RN: Up-regulation of cyclooxygenase 2 gene expression in human colorectal adenomas and adenocarcinomas. Gastroenterology 107: 1183-1188, 1994. (Pubitemid 24294584)
13. Sano H, Kawahito Y, Wilder RL, et al: Expression of cyclooxygenase-1 and -2 in human colorectal cancer. Cancer Res 55: 3785-3789, 1995.
14. Yoshimi N, Shimizu M, Matsunaga K, Yamada Y, Fujii K and Mori H: Chemopreventive effect of N-(2-cyclohexyloxy-4-nitrophenyl) methane sulfonamide (NS-398), a selective cyclooxygenase-2 inhibitor, in rat colon carcinogenesis induced by azoxymethane. Jpn J Cancer Res 90: 406-412, 1999. (Pubitemid 29213545)
15. Erickson BA, Longo WE, Panesar N, Mazuski JE and Kaminski DL: The effect of selective cyclooxygenase inhibitors on intestinal epithelial cell mitogenesis. J Surg Res 81: 101-107, 1999. (Pubitemid 29393786)
16. Li M, Wu X and Xu XC: Induction of apoptosis in colon cancer cells by cyclooxygenase-2 inhibitor NS 398 through a cytochrome c-dependent pathway. Clin Cancer Res 7: 1010-1016, 2001. (Pubitemid 32708740)
17. Hanif R, Pittas A, Feng Y, et al: Effect of non-steroidal anti-inflammatory drugs on proliferation and on induction of apoptosis. Biochem Pharmacol 55: 53-64, 1998. (Pubitemid 28101985)
18. Williams CS, Watson AJ, Sheng H, Helou R, Shao J and DuBois RN: Celecoxib prevents tumor growth in vivo without toxicity to normal gut: lack of correlation between in vitro and in vivo model. Cancer Res 60: 6045-6051, 2000.
19. Chan TA, Morin PJ, Vogelstein B and Kinzler KW: Mechanisms underlying nonsteroidal antiinflammtory drug-mediated apoptosis. Proc Natl Acad Sci USA 95: 681-686, 1998. (Pubitemid 28083803)
20. Chen WS, Wei SJ, Liu JM, Hsiao M, Kou-Lin J and Yang WK: Tumor invasiveness and liver metastasis of colon cancer cells correlated with cyclooxygenase-2 (COX-2) expression and inhibited by a COX-2-selective inhibitor, Etodolac. Int J Cancer 91: 894-899, 2001. (Pubitemid 32178662)
21. Tsujii M, Kawano S and DuBois RN: Cyclooxygenase-2 expression in human colon cancer cells increases metastatic potential. Proc Natl Acad Sci USA 94: 3336-3340, 1997. (Pubitemid 27157312)
22. Attiga FA, Fernandez PM, Weeraratna AT, Manyak MJ and Patierno SR: Inhibitors of prostaglandin synthesis inhibit human prostate tumor cell invasiveness and reduce the release of matrix metalloproteinases. Cancer Res 60: 4629-4637, 2000. (Pubitemid 32103650)
23. Tsujii M, Kawano S, Tsujii S, Sawaoka H, Hori M and DuBois RN: Cyclooxygenase regulates angiogenesis induced by colon cancer. Cell 93: 705-716, 1998. (Pubitemid 28257578)
24. Jones MK, Wang H, Peskar BM, Levin E, Itani RM, Sarfeh IJ and Tarnawski AS: Inhibition of angiogenesis by nonsteroidal anti-inflammatory drugs; insight into mechanism and implication for cancer growth and ulcer healing. Nat Med 5: 1418-1423, 1999.
25. Daniel TO, Liu H, Morrow JD, Crews BC and Marnett LJ: Thromboxane A2 is a mediator of cyclooxygenase-2-dependent endothelial migration and angiogenesis. Cancer Res 59: 4574-4577, 1999. (Pubitemid 29428961)
26. Nagatsuka I, Yamada N, Shimizu S, Ohira M, Nishino H, Seki S and Hirakawa K: Inhibitory effect of a selective COX-2 inhibitor on liver metastasis of colon cancer. Int J Cancer 100: 515-519, 2002. (Pubitemid 34816150)
27. Yamada N, Chung YS, Takatsuka S, Arimoto Y, Sawada T, Dohi T and Sowa M: Increased sialyl Lewis A expression and fucosyltransferase activity with acquisition of a high metastatic capacity in a colon cancer cell line. Br J Cancer 76: 582-587, 1997. (Pubitemid 27354670)
28. Fukushima M, Satake H, Uchida J, et al: Preclinical antitumor efficacy of S-1: A new oral formulation of 5-fluorouracil on human tumor xenografts. Int J Oncol 13: 693-698, 1998.
29. Inoue K, Motonaga A, Suzuka H, et al: Effect of etodolac on type-II collagen-induced arthritis in mice. Agents Actions 39: 187-194, 1993. (Pubitemid 23349829)
30. Yamazaki R, Kusunoki N, Matsuzaki T, Hashimoto S and Kawai S: Selective cyclooxygenase-2 inhibitors show a differential ability to inhibit proliferation and induce apoptosis of colon adenocarcinoma cells. FEBS Lett 531: 278-284, 2002. (Pubitemid 35341208)
31. Nishimura G, Yanoma S, Mizuno H, Kawakami K and Tsukuda M: A selective cyclooxygenase-2 inhibitor suppresses tumor growth in nude mouse xenografted with human head and neck squamous carcinoma cells. Jpn J Cancer Res 90: 1152-1162, 1999.
32. Abiru S, Nakao K, Ichikawa T, et al: Aspirin and NS-398 inhibit hepatocyte growth factor-induced invasiveness of human hepatoma cells. Hepatology 35: 1117-1124, 2002. (Pubitemid 34454008)
33. Nishimura G, Yanoma S, Satake K, et al: An experimental model of tumor dormacy therapy for advanced head and neck carcinoma. Jpn J Cancer Res 91: 1199-1203, 2000.
34. Kakiuchi Y, Tsuji S, Tsujii M, et al: Cyclooxygenase-2 activity altered the cell-surface carbohydrate antigens on colon cancer cells and enhanced liver metastasis. Cancer Res 62: 1567-1572, 2002. (Pubitemid 34407824)
35. Chapple KS, Cartwright EJ, Hawcroft G, et al: Localization of cyclooxygenase-2 in human sporadic colorectal adenomas. Am J Pathol 156: 545-553, 2000. (Pubitemid 30643810)
36. Leahy KM, Omberg RL, Wang Y, Zweifel BS, Koki AT and Masferrer JL: Cyclooxygenase-2 inhibition by celecoxib reduces proliferation and induces apoptosis in angiogenic endothelial cells in vivo. Cancer Res 62: 625-631, 2002. (Pubitemid 34126930)
37. Ota S, Tanaka Y, Bamba H, Kato A, and Matsuzaki F: Nonsteroidal anti-inflammatory drugs may prevent colon cancer through suppression of hepatocyte growth factor expression. Eur J Pharmacol 367: 131-138, 1999.
38. Kojima M, Morisaki T, Uchiyama A, Doi F, Mibu R, Katano M and Tanaka M: Association of enhanced cyclooxygenase-2 expression with possible local immunosuppression in human colorectal carcinomas. Ann Surg Oncol 8: 458-465, 2001. (Pubitemid 32524771)
39. Huang M, Stolina M, Sharma S, et al: Non-small cell lung cancer cyclooxygenase-2-dependent regulation of cytokine balance in lymphocytes and macrophages: up-regulation of interleukin 10 and down-regulation of interleukin 12 production. Cancer Res 58: 1208-1216, 1998. (Pubitemid 28183210)
40. Shimizu S, Yamada N, Sawada T, et al: In vivo and in vitro interactions between human colon carcinoma cells and hepatic stellate cells. Jpn J Cancer Res 91: 1285-1295, 2000. (Pubitemid 32042364)
41. Yonekura K, Basaki Y, Chikahisa L, et al: UFT and its metabolites inhibit the angiogenesis induced by murine renal cell carcinoma, as determined by dorsal air sac assay in mice. Clin Cancer Res 5: 2185-2191, 1999. (Pubitemid 29399276)